Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
252 Leser
Artikel bewerten:
(1)

Mural Health and China-based Clinflash Partner to Expand Global Patient Payment Solutions

The strategic partnership marks an important milestone for the industry as Mural Health and Clinflash platforms enable international sponsors to deliver patient payments globally, including China.

BERWYN, Pa., May 23, 2023 /PRNewswire/ -- Mural Health, a clinical trials technology company that improves the patient and caregiver experience in order to improve enrollment rates, participant retention, and increase protocol compliance, has today announced a strategic partnership with Clinflash, a leading provider of information technology in field of clinical development. Building on Clinflash's IT specialism in clinical trials, the partnership will expand the capacity and global market of patient payments for clinical trials. Having reached an exclusive global agreement the partnership consolidates technical, market and commercial forces, enabling sponsors to access patient payment solutions in the Chinese market and beyond. The two organizations are currently preparing for further collaboration projects.

Mural Health, through their participant management platform Mural Link, has introduced a next generation patient payments platform which drives strategic value by facilitating participation in clinical research, thereby improving study operation and the quality of clinical data sets.

Clinflash ePAY (Clinical Trial Electronic Payment Solution) uses leading digital service technology to improve payment efficiency and safeguard the interests of subjects, sponsors, researchers, and other parties. The company already has established close cooperation with dozens of key hospitals in China to provide third-party mobile payment solutions for Chinese trial participants.

This strategic cooperation is an important milestone for both Mural Health and Clinflash, as the two organizations have joined forces to deepen their technical portfolio and broaden their commercialization in the technical patient payments field.

Mural Health's Co-Founder and Co-CEO, Sam Whitaker said: "We are thrilled to be working with Clinflash on this collaboration which comes at an exciting time for both of our organizations. This partnership looks to strengthen the commercialization capabilities of both the Clinflash and Mural Link technologies, as we ease accessibility to the Chinese clinical trials market for sponsors from across the globe."

Commenting on the partnership, Gary Guan, GM at Clinflash said, "This is an exciting development both for our business and the markets we serve. Clinflash has a strong reputation within China and with our Chinese partners across the health ecosystem. Working alongside Mural Health and sharing our technical and market insights, we look forward to improving payment efficiency and expanding our market both within China and beyond."

About Mural Health

Mural Health is a next-generation participant management platform. The Company's Mural Link technology platform is designed to make it easier to participate in clinical trials, thereby improving study operation and the quality of clinical data sets. Mural Link offers next-generation participant payment technology that gives participants the power to choose how they receive payment, eliminates predatory fees related to prepaid debit cards, introduces functionality to help patients arrive at site visits (without incurring a cash expense), empowers communication between participants and site personnel, and captures participant data to predict individuals who are likely to drop-out. The Mural Link platform can be easily deployed to positively improve participant retention and engagement, increase protocol compliance, and increase enrollment rates. Please reach out to us to learn more about or capabilities, www.muralhealth.com or general@muralhealth.com.

About Clinflash

Clinflash, founded in 2014 in China, specializes in IT systems for clinical trials, including Clinflash EDC, Clinflash IRT, Clinflash Safety, Clinflash ePRO, Clinflash CTMS, Clinflash eTMF, Clinflash eCTD, and Clinflash ePAY. Clinflash systems are widely applied in large scale registration and post-market studies, both within China and globally, serving local and multinational corporations, R&D, pharma customers of branded drugs, generics, medical devices, IVD, etc.

Clinflash enjoys an excellent reputation thanks to its in-depth industry insight, robust technological expertise and outstanding quality management systems. The company works with leading healthcare companies and Clinical Research Organization (CRO) partners, providing systems and supporting services to 3000+ clinical trial projects. For additional information, please visit us on our website: www.clinflash.com or contact us at bd@clinflash.com.

Cision View original content:https://www.prnewswire.co.uk/news-releases/mural-health-and-china-based-clinflash-partner-to-expand-global-patient-payment-solutions-301832009.html

© 2023 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.